Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation

Cerebrovascular Diseases

Volumn 35, Issue 4, 2013, Pages 320-326

  Chevalier, Julie ^a,b   Giroud, Maurice ^b   De Pouvourville, Gérard ^a  

^a ESSEC BUSINESS SCHOOL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Atrial fibrillation; Dabigatran; Modeling

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SUBARACHNOID HEMORRHAGE; VERY ELDERLY;

EID: 84876456163     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000347074     Document Type: Article

References (22)

1. Le Heuzey JY: Epidémiologie, étiologie et mécanisme de la fibrillation atriale. Bull Acad Natl Méd 2011; 195: 953-962.
2. Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ: Stroke associated with atrial fibrillation -incidence and early outcomes in the North Dublin Population Stroke Study. Cerebrovasc Dis 2010; 29: 43-49.
3. Tu HT, Campbell BC, Christensen S, Collins M, De Silva DA, Butcher KS, Parsons MW, Desmond PM, Barber PA, Levi CR, Bladin CF, Donnan GA, Davis SM: Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis 2010; 30: 389-395.
4. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from 5. randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RELY Steering Committee and Investigators: Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L: Newly Identified Events in the RELY Trial. N Engl J Med 2010; 363: 1875-1876.
7. Cegedim Strategic Data: La segmentation des patients FA selon les définitions RE-LY chez les médecins généralistes. Market research report to Boehringer Ingelheim France, October 2010.
8. Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM: Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010; 104: 1106-1115.
9. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441-2448.
10. Bejot Y, Rouaud O, Benatru I, Fromont A, Couvreur G, Caillier M: Les apports du registre dijonnais des accidents vasculaires cérébraux en 20. ans d'activité. Rev Neurol 2008; 16: 138-147.
11. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS: The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151: 297-305.
12. Banerjee A, Lane DA, Torp-Pedersen C, Lip GYH: Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 2012; 107: 584-589.
13. Kansal RA, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR: Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012; 98: 573-578.
14. Pink J, Lane S, Pirmohamed M, Hughes DA: Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 2011; 343:d6333.
15. Sorensen SV, Kansal RA, Connolly S, Peng S Linnehan J, Bradley-Kennedy C, Plumb JM: Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.
16. Pengo V, Crippa L Falanga A, Finazz G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C: Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2011; 106: 868-876.
17. AFSSAPS: Suivi biologique du traitement par antivitamine K (étude 2003). January 2004. http://ansm.sante.fr/Dossiers-thematiques/ Anti-vitamine-K-AVK/Etudes-et-enquetessur-les-AVK.
18. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
19. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB: Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764.
20. Kaarisalo MM, Immonen-Räihä P, Marttila RJ, Salomaa V, Kaarsalo E, Salmi K, Sarti C, Sivenius J, Torppa J, Tuomilehto J: Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke 1997; 28: 311-315.
21. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, Spolveri S, Baruffi MC, Landini G, Ghetti A, Wolfe CD, Inzitari D: Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the European Community Stroke Project). Stroke 2001; 32: 392-398.
22. Penado S, Cano M, Acha O, Hernández JL, Riancho JA: Atrial fibrillation as a risk factor for stroke recurrence. Am J Med 2003; 114: 206-210.